Literature DB >> 24739416

The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.

Israel Muro1, Gloria Fang1, Kacie A Gardella1, Indra M Mahajan1, Casey W Wright1.   

Abstract

T cells devoid of tumor necrosis factor receptor associated factor-3 (Traf3) exhibit decreased proliferation, sensitivity to apoptosis, and an improper response to antigen challenge. We therefore hypothesized that TRAF3 is critical to the growth of malignant T cells. By suppressing TRAF3 protein in different cancerous T cells, we found that anaplastic large cell lymphoma (ALCL) cells require TRAF3 for proliferation. Since reducing TRAF3 results in aberrant activation of the noncanonical nuclear factor-κB (NF-κB) pathway, we prevented noncanonical NF-κB signaling by suppressing RelB together with TRAF3. This revealed that TRAF3 regulates proliferation independent of the noncanonical NF-κB pathway. However, suppression of NF-κB-inducing kinase (NIK) along with TRAF3 showed that high levels of NIK have a partial role in blocking cell cycle progression. Further investigation into the mechanism by which TRAF3 regulates cell division demonstrated that TRAF3 is essential for continued PI3K/AKT and JAK/STAT signaling. In addition, we found that while NIK is dispensable for controlling JAK/STAT activity, NIK is critical to regulating the PI3K/AKT pathway. Analysis of the phosphatase and tensin homolog (PTEN) showed that NIK modulates PI3K/AKT signaling by altering the localization of PTEN. Together our findings implicate TRAF3 as a positive regulator of the PI3K/AKT and JAK/STAT pathways and reveal a novel function for NIK in controlling PI3K/AKT activity. These results provide further insight into the role of TRAF3 and NIK in T cell malignancies and indicate that TRAF3 differentially governs the growth of B and T cell cancers.

Entities:  

Keywords:  JAK/STAT; NF-κB; NIK; PI3K/AKT; TRAF3

Mesh:

Substances:

Year:  2014        PMID: 24739416      PMCID: PMC4111755          DOI: 10.4161/cc.28895

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

1.  NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 2.  NF-kappaB in cancer: from innocent bystander to major culprit.

Authors:  Michael Karin; Yixue Cao; Florian R Greten; Zhi-Wei Li
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

3.  Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Authors:  J O Lee; H Yang; M M Georgescu; A Di Cristofano; T Maehama; Y Shi; J E Dixon; P Pandolfi; N P Pavletich
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

4.  A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Biol Chem       Date:  2001-12-28       Impact factor: 5.157

5.  Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs.

Authors:  Ping Xie; Laura L Stunz; Karen D Larison; Baoli Yang; Gail A Bishop
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

6.  IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors.

Authors:  Sonja E Johnson; Nisha Shah; Anna A Bajer; Tucker W LeBien
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

7.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

8.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

9.  RelB forms transcriptionally inactive complexes with RelA/p65.

Authors:  Ralf Marienfeld; Michael J May; Ingolf Berberich; Edgar Serfling; Sankar Ghosh; Manfred Neumann
Journal:  J Biol Chem       Date:  2003-03-25       Impact factor: 5.157

10.  Synergistic effects of interleukin-7 and pre-T cell receptor signaling in human T cell development.

Authors:  Ekta S Patel; Lung-Ji Chang
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

View more
  10 in total

1.  Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.

Authors:  Benigno C Valdez; Jonathan E Brammer; Yang Li; David Murray; Esmeralda C Teo; Yan Liu; Chitra Hosing; Yago Nieto; Richard E Champlin; Borje S Andersson
Journal:  Leuk Res       Date:  2016-05-27       Impact factor: 3.156

2.  Nuclear factor-κB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1).

Authors:  Sunhee Lee; Madhavi Challa-Malladi; Shawn B Bratton; Casey W Wright
Journal:  J Biol Chem       Date:  2014-09-22       Impact factor: 5.157

Review 3.  TRAF3 as a powerful and multitalented regulator of lymphocyte functions.

Authors:  Gail A Bishop
Journal:  J Leukoc Biol       Date:  2016-05-06       Impact factor: 4.962

4.  Romidepsin targets multiple survival signaling pathways in malignant T cells.

Authors:  B C Valdez; J E Brammer; Y Li; D Murray; Y Liu; C Hosing; Y Nieto; R E Champlin; B S Andersson
Journal:  Blood Cancer J       Date:  2015-10-16       Impact factor: 11.037

5.  Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity.

Authors:  Kacie A Gardella; Israel Muro; Gloria Fang; Krishnakali Sarkar; Omayra Mendez; Casey W Wright
Journal:  Oncotarget       Date:  2016-03-08

6.  Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia.

Authors:  Yan Xiu; Qianze Dong; Qingchang Li; Fengyin Li; Nick Borcherding; Weizhou Zhang; Brendan Boyce; Hai-Hui Xue; Chen Zhao
Journal:  Cell Rep       Date:  2018-01-09       Impact factor: 9.423

7.  TRAF3 enhances TCR signaling by regulating the inhibitors Csk and PTPN22.

Authors:  Alicia M Wallis; Ellie C Wallace; Bruce S Hostager; Zuoan Yi; Jon C D Houtman; Gail A Bishop
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

8.  SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.

Authors:  Jun Ding; Daming Qin; Yong Zhang; Qinghe Li; Yi Li; Jinmao Li
Journal:  Mol Med Rep       Date:  2020-01-03       Impact factor: 2.952

Review 9.  Genetic Alterations of TRAF Proteins in Human Cancers.

Authors:  Sining Zhu; Juan Jin; Samantha Gokhale; Angeli M Lu; Haiyan Shan; Jianjun Feng; Ping Xie
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

10.  Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.

Authors:  Gema Perez-Chacon; Magdalena Adrados; Maria T Vallejo-Cremades; Sophie Lefebvre; John C Reed; Juan M Zapata
Journal:  Front Immunol       Date:  2019-01-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.